Expertise in
15
conditions

Dr. David L. Watkins

Oncology
400 Rosalind Redfern Grover Pkwy Ste 100, 
Midland, TX 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
400 Rosalind Redfern Grover Pkwy Ste 100, 
Midland, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Watkins is an Oncologist in Midland, Texas. Dr. Watkins is highly rated in 15 conditions, according to our data. His top areas of expertise are Pleuropulmonary Blastoma, Paget Disease of the Breast, Breast Cancer, and Lung Adenocarcinoma. Dr. Watkins is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in TX
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Moda Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

400 Rosalind Redfern Grover Pkwy Ste 100, Midland, TX 79701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Expertise in
8
conditions
Dr. Pankaj K. Khandelwal
Oncology
Expertise in
8
conditions
Dr. Pankaj K. Khandelwal
Oncology

Texas Oncology PA

500 W 3rd St, 
Odessa, TX 
 (19.9 miles away)
432-335-8275
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pankaj Khandelwal is an Oncologist in Odessa, Texas. Dr. Khandelwal is highly rated in 8 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Colorectal Cancer, Familial Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Khandelwal is currently accepting new patients.

Expertise in
34
conditions
Dr. Manmeet S. Mangat
Hematology Oncology | Hospital Medicine | Oncology
Expertise in
34
conditions
Dr. Manmeet S. Mangat
Hematology Oncology | Hospital Medicine | Oncology

Texas Oncology PA

400 Rosalind Redfern Grover Pkwy, Suite 100, 
Midland, TX 
 (1.1 miles away)
432-687-1949
Languages Spoken:
English, Hindi, Punjabi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Manmeet Mangat is a Hematologist Oncology specialist and a Hospital Medicine provider in Midland, Texas. Dr. Mangat is highly rated in 34 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Colorectal Cancer, Lynch Syndrome, and Bone Marrow Aspiration. Dr. Mangat is currently accepting new patients.

Expertise in
11
conditions
Dr. Ashutosh Rastogi
Oncology | Hematology Oncology
Expertise in
11
conditions
Dr. Ashutosh Rastogi
Oncology | Hematology Oncology
301 N N St, 
Midland, TX 
 (1.0 miles away)
432-685-1559
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Ashutosh Rastogi is an Oncologist and a Hematologist Oncology provider in Midland, Texas. Dr. Rastogi is highly rated in 11 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia. Dr. Rastogi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Watkins's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 8 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile